Using the ELISA method, we found that the mean concentrations of both APL1β28 and clusterin were not significantly different between the control and aMCI groups. The APL1β28 levels were positively correlated with clusterin and that both were negatively correlated with the MMSE scores of the aMCI patients. Clusterin levels were negatively correlated with the MoCA and CASI scores of the aMCI patients. Using multivariate analysis, the correlation between clusterin and MMSE/MoCA/ CASI was independent of other AD risk factors including age, education, sex, body mass index and ApoE genotype. The data presented here demonstrate that plasma clusterin levels reflect cognitive function in aMCI patients. Amnestic mild cognitive impairment (aMCI), which affects 5-6% of people older than 65, is a syndrome attributed to people with noticeable impairments in memory function but whose other cognitive functions are normal [1] [2] [3] [4] [5] [6] [7] [8] . Similar to other forms of mild cognitive impairment (MCI) such as non-memory (nmMCI) and multi-domain (mMCI) subtypes, aMCI patients retain normal daily activities. It is estimated that, annually, 7% of MCI cases convert to Alzheimer's disease (AD) and other dementia subtypes 9, 10 , chronic diseases in which the progression of brain changes and cognitive impairments usually appear 10-20 years before the clinical diagnosis. Similar to AD and other forms of MCI, the exact causes of aMCI are not clearly understood, though age and family history are shown to be risk factors. There currently is no cure for dementia, including AD, and most clinical trials targeting AD patients in the dementia phases have not shown promising effects. As a result, there have been mounting efforts to identify disease-related changes in the pre-dementia phase, such as in aMCI, for early diagnosis and intervention.
Amnestic mild cognitive impairment (aMCI), which affects 5-6% of people older than 65, is a syndrome attributed to people with noticeable impairments in memory function but whose other cognitive functions are normal [1] [2] [3] [4] [5] [6] [7] [8] . Similar to other forms of mild cognitive impairment (MCI) such as non-memory (nmMCI) and multi-domain (mMCI) subtypes, aMCI patients retain normal daily activities. It is estimated that, annually, 7% of MCI cases convert to Alzheimer's disease (AD) and other dementia subtypes 9, 10 , chronic diseases in which the progression of brain changes and cognitive impairments usually appear 10-20 years before the clinical diagnosis. Similar to AD and other forms of MCI, the exact causes of aMCI are not clearly understood, though age and family history are shown to be risk factors. There currently is no cure for dementia, including AD, and most clinical trials targeting AD patients in the dementia phases have not shown promising effects. As a result, there have been mounting efforts to identify disease-related changes in the pre-dementia phase, such as in aMCI, for early diagnosis and intervention.
At this time, the diagnosis of aMCI depends mainly on a comprehensive medical evaluation that includes neuropsychological testing and assessment of the patient's history [11] [12] [13] [14] [15] [16] [17] [18] [19] . Biomarkers, including imaging and biochemical substances in the body fluids, assist the disease diagnosis and allow for the monitoring of the pathogenesis. For example, magnetic resonance imaging (MRI) has shown atrophy in the medial temporal lobe, including the hippocampus and entorhinal cortex, in MCI (including aMCI) and AD populations 5, [20] [21] [22] [23] , and carbon 11-labeled PiB (Pittsburgh compound B) PET has demonstrated increased brain amyloid burden in aMCI and AD patients 23, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] . In addition to imaging methods 13, [32] [33] [34] [35] , body fluid biomarkers are attracting more attention due to their direct relevance to the biology of dementia [36] [37] [38] [39] . Low concentrations of Aβ 42 and high concentrations of total and phosphorylated tau have been detected in the CSF of MCI and AD populations from mono-center and multi-center longitudinal studies [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] . Diagnostic sensitivity to CSF Aβ 42 and Tau in MCI patients due to AD is about 50-90%, and the specificity is 80-100% [40] [41] [42] [43] [44] 50 . Moreover, compared to MRI and CSF biomarkers, the use of plasma biomarkers as a diagnostic tool is relatively low-cost and non-invasive. Based on CSF biomarker studies and on MRI, brain atrophy and Aβ deposits in the patient's brain suggest that Aβ and proteins implicated in Aβ metabolism are potential monitors for AD and MCI pathogenesis 37, 38, [51] [52] [53] [54] [55] . Generated by similar β -and γ -cleavages on amyloid-like protein 1 (APLP1, another member of the amyloid precursor protein [APP] gene family), which also includes APLP2 and APP), APL1β 28 was recently reported to be a surrogate biomarker for AD with the use of mass spectroscopy 56 . Similar to APP, which produces the amyloid beta species (Aβ 40, Aβ 42), a component of senile plaque [57] [58] [59] , APLP1 undergoes α -, β -and γ -secretase; unlike APP, however, no Aβ peptide is generated due to the lack of an Aβ sequence in the gene [60] [61] [62] [63] . The APL1β 28 level is higher in the CSF of patients with MCI and familial Alzheimer's disease (FAD), as well as that in patients with sporadic AD 56, 64 . Besides the Aβ -related APP gene family, proteins implicated in APP metabolism are also potential targets for biomarkers. Clusterin, the third-strongest genetic risk factor for late-onset Alzheimer's disease (LOAD), is implicated in the clearance process of Aβ accumulation and is associated with the rate of cognitive decline [65] [66] [67] [68] [69] [70] . Clusterin, also called apolipoprotein J, is a disulfide-linked heterodimeric protein whose SNPs, according to genome-wide association studies, are linked to AD 71, 72 . Moreover, increased levels of CSF clusterin have been found to be connected to entorhinal atrophy in AD and MCI patients with high Aβ deposition. Plasma clusterin concentration has been reported to be associated with Mini-Mental State Examination (MMSE) scores in combined MCI/ AD cohorts 73 . However, the relationship between the plasma concentrations of APL1β 28 and clusterin, two potential biomarkers implicated in APP processing and metabolism, has not been examined in the aMCI population.
Furthermore, there are a number of risk factors that are strongly linked with SAD. For example, the strongest genetic risk factor in the pathogenesis for LOAD and MCI is considered to be ApoE polymorphisms [74] [75] [76] [77] . Epidemiological studies have shown that age is the most dominant risk factor for the development of AD and MCI [78] [79] [80] ; a high level of education has also been connected to a lower incidence of AD 81, 82 . Body mass index (BMI) has been shown to be associated with the CSF biomarkers of amyloid and tau in MCI patients 83 . Thus, whether these factors, combined with plasma APL1β 28 and clusterin levels, might have a synergic effect remains to be determined. In the current study, we focused our analysis on aMCI populations and aimed to investigate whether plasma levels of APL1β 28 and clusterin are correlated with cognitive status in the aMCI population and whether these correlations have relationships with other risk factors associated with aMCI and AD.
Results
Forty-seven aMCI patients and thirty-five age-matched healthy controls were recruited for our study. All patients were of Chinese Han ethnicity. Detailed demographic data of all aMCI and NC subjects are presented in Table 1 . The enzyme-linked immunosorbent assay (ELISA) was performed to determine the absolute concentrations of APL1β 28 and clusterin in plasma ([APL1β 28] plasma and [clusterin] plasma , respectively), and we adopted ELISA methods that have been applied and validated previously 73 . The standard curves for APL1β 28 (Supplementary Figure 1) and clusterin (Supplementary Figure 2) show reliable and reproducible measurements. Our data indicate that the mean [APL1β 28] plasma and [clusterin] plasma levels were not significantly different between the aMCI and control groups (APL1β 28: aMCI group, 2.51 ± 0.15 ng/ml, NC group, 2.41 ± 0.17 ng/ml, p = 0.66; clusterin: aMCI group, 115.27 ± 4.30 μ g/ ml, NC group, 120.32 ± 6.87 μ g/ml, p = 0.52). We then performed a one-sample Kolmogorov-Smirnov test on plasma APL1β and clusterin concentrations, and on the MMSE, MoCA, CASI scores in the aMCI and NC groups. All data followed a normal distribution except for the MMSE scores in the NC group (Table S1 ). We thus adopted Spearman's rank correlation analysis for all the correlations with MMSE in the NC group and Pearson's correlation for all other correlation analyses. We tested the correlations between plasma APL1β 28 and clusterin levels using scores from the MMSE, which is the most widely used screening instrument for cognitive deficits. As shown in race, education, and language ability 84, 85 . Thus, other dementia screening tools have been developed and are well known to allow a more comprehensive understanding of other cognitive domains. The CASI, introduced in 1994, features a scale of 100 points 86 and combines the MMSE and the Hasegawa Dementia Rating Scale (HDRS) 87 . Featuring more detailed assessments and broader scoring ranges, the CASI is considered more useful for determining the severity of dementia. In our study, [clusterin] plasma was also found to be negatively correlated with CASI scores in the aMCI subjects ( Fig Age is unquestionably the strongest risk factor for the development of AD and MCI [78] [79] [80] . Thus, we performed multivariate analysis to evaluate whether age is a factor in the correlations between APL1β 28 or clusterin levels in plasma and MMSE/MoCA/CASI scores. Our data show that the correlations of clusterin or APL1β 28levels with MMSE scores were independent of age ( Table 2) . After adjusting for age, the correlations of clusterin levels with MoCA or CASI scores remained significant, and those of APL1β 28 remained not significant. Next, we tested whether education level or sex might affect these correlations. As summarized in Table 2 , after adjusting for education and sex, clusterin levels correlate with MMSE, MoCA and CASI significantly; however, only the correlation efficiency of APL1β 28 with MMSE showed a trend toward significance (p = 0.055 and 0.059, respectively). The correlation of APL1β 28 with MoCA and CASI remained not significant after adjusting for education and sex.
The strongest genetic risk factor in the pathogenesis for AD and MCI is ApoE polymorphisms [74] [75] [76] [77] . To determine whether there is interaction between the ApoE genotype and plasma APL1β 28 and clusterin levels, we compared the average levels of these two proteins in the blood of ApoE ε4-carriers and non-carriers. We used Sanger's sequencing to examine the ApoE polymorphisms in aMCI and control groups and found that 27.7% of the aMCI patients (13 out of 47) and 25.7% of the control patients (9 out of 35) carried a single copy of ApoE ε 4 allele, while no subject carrying two copies was identified in either the aMCI or control groups. Our results show that the plasma levels of APL1β 28 and clusterin are not affected by the presence/absence of ApoE ε 4 allele (Fig. 3A) . Furthermore, we tested the effects of ApoE genotype on the correlations between these two proteins with cognitive scores. The data showed that ApoE genotype has no effect on clusterin's correlation with MMSE, MoCA and CASI scores, but that it increased the correlation efficiency of APL1β 28 with the MMSE score from 0.046 to 0.053. To determine whether BMI is associated with plasma APL1β 28 and clusterin levels, we plotted the concentration versus the BMI measured at the time of clinical examination. As shown in 
Discussion
In this study, we found that the MMSE scores reflecting cognitive ability were negatively correlated with plasma APL1β 28 and clusterin levels in aMCI patients but not in the levels of healthy controls. In addition, the plasma clusterin level was also correlated with CASI and MoCA scores in the aMCI population. These results are consistent with findings showing that APL1β 28 and clusterin levels in CSF are altered in the MCI, PS1-FAD, and sporadic AD patients 56, 89, 90 . Since the distribution of MMSE scores in the NC groups were within a narrow range and did not follow a normal distribution, we performed parametric analysis (Pearson's correlation) and non-parametric analysis (Spearman's rank correlation) and found no correlations in the NC groups.
The correlation between clusterin and MMSE, MoCA or CASI seems specific, since it is independent of age, education level, BMI, and ApoE polymorphisms, as revealed by multivariate analysis. Furthermore, plasma clusterin and APL1β 28 levels showed a very strong correlation in both aMCI and control subjects, a finding that is consistent with the notion that they are both involved in the processing of APP. These observations add to the existing evidence that suggests a convergent role of APP dysfunction in the decline of cognitive ability. This finding is consistent with previous reports showing that clusterin interacts with Aβ to cause AD pathology. For instance, clusterin concentrations in CSF show a significant interaction with CSF Aβ 1-42 on the atrophy rate of the entorhinal cortex in AD and MCI patients, as well as that in healthy controls 89 . Moreover, plasma clusterin levels have been found to be an indicator for the rate of cognitive decline and brain atrophy in AD patients 73, 89, 91, 92 . Although Aβ 25-35 treatment of primary neurons elevates intracellular clusterin levels and reduces extracellular-secreted clusterin specifically, treatment with other stressors, including MG132 (the proteasome inhibitor), and ultraviolet irradiation causes cell death without significant changes in clusterin levels. Furthermore, the inactivation of clusterin expression in neurons reduces Aβ -mediated neurotoxicity 93 . In transgenic mice carrying FAD mutations (PS1M146V, APP Swe, and tauP301L), clusterin in the serum has been reduced by about 30%; this reduction can be fully rescued by treating the mice with coenzyme Q10 94 . When compared to those of clusterin, the correlations of APL1β 28 with cognitive scores are rather weak, reaching a significant level only when correlated with MMSE (p = 0.046) but not when correlated with MoCA or CASI. Furthermore, after adjustment for sex, education level or ApoE genotype, the correlation remains not significant (p = 0.05-0.06). We speculate that there might be two possibilities for this: the first is that the weak correlation between APL1β 28 with MMSE is because APL1β 28 strongly correlates with clusterin, and clusterin in turn strongly correlates with MMSE. That is to say, the [APL1β 28] plasma -MMSE correlation is a consequence of clusterin's effect on the cognitive ability of aMCI subjects. The second possibility is that the plasma levels of APL1β 28 might not accurately reflect the secretase activity in the brain. Therefore, further studies are required to determine whether APL1β share identical cleavage processes with Aβ and whether the levels of [APL1β 28] plasma correlate with brain enzymatic activity of α -, β -, and γ -secretase and the severity of Aβ peptides deposition in the brain.
Despite the significant increases of CSF clusterin and APL1β 28 in AD and MCI patients, the average levels of [APL1β 28] plasma and [clusterin] plasma were not different in the aMCI subjects compared to those in the healthy controls, a result that is consistent with a previous study by Thambisetty et al. 73 . We found that aMCI patients showed an increased trend in clusterin levels and trended toward a decreasing performance in cognitive tests, changes that are identified as potential candidates for early events in the pre-dementia stages. Interestingly, we found that the average levels of [APL1β 28] plasma and [clusterin] plasma were not different in the ApoE ε4-carriers and non-carriers. Similar to ApoE, clusterin targets at amyloid-β aggregation and clearance, lipid homeostasis which is related to the pathogenesis of AD [65] [66] [67] [68] [69] . However, the relationship between ApoE ε 4 subtypes and brain clusterin levels remains elusive, which might be due to the complication of this disease 95 . Furthermore, whether the plasma clusterin level reflects the brain clusterin level needs further investigation. In our current study, we did not have enough aMCI-AD conversion cases due to the limited number of aMCI patients and a relatively short monitoring period post-diagnosis. Follow-up cohort studies are needed to evaluate whether the plasma levels of APL1β 28 and clusterin could serve as indicators for the conversion rate of aMCI to AD in a Chinese population.
Materials and Methods
Ethics statement. All experiments were conducted in accordance with protocols approved by the institutional review board of Peking University Institute of Mental Health. Legally binding informed consent was obtained from all subjects.
Subjects. All study participants were mainland China citizens of Han ethnicity who were prospectively recruited to establish a case registry at the Dementia Care and Research Center, Peking University Institute of Mental Health. The study, which was conducted from 2006 to 2011, included 47 individuals with amnestic mild cognitive impairment (the aMCI group) and 35 healthy adult controls (the NC group). All the subjects received a clinical review and a battery of neuropsychological tests and laboratory tests; standing body weight was measured with an electronic scale, height (without shoes) was measured with an anthropometer, and the BMI was computed based on these parameters (kg weight/m 2 height).The education level was equated to the amount of time the participant spent in school (elementary school through graduate school).
Diagnostic criteria.
The clinical diagnosis of amnestic MCI was based on the criteria established by Petersen 96 . The diagnostic criteria of aMCI were defined as follows: (1) age ≥ 50 years and met the Petersen criteria; (2) complained of memory impairment that (preferably) could be corroborated by another individual; (3) the impaired memory function was not compatible with patient's age and/or education; (4) the total MMSE score was no less than 24, and the CDR score was not more than 0.5; (5) the activities of daily living were intact; and (6) DSM-IV criteria for the diagnosis of dementia was not met. The exclusion criteria were as follows: (1) diagnosed with other neurodegenerative disease; (2) cognitive dysfunction was induced by traumatic brain injuries, tumor or infection; (3) cognitive dysfunction was induced by alcohol or drug use; and (4) cognitive dysfunction was induced for reasons other than mentioned above.
Inclusion criteria for the normal control (NC) group were (1) age ≥ 50 years; (2) no serious physical diseases; and (3) normal cognitive function.
Neuropsychological assessment. These tests were administered using standardized procedures as previously described 97, 98 . In brief, the neuropsychological tests were conducted in Chinese by well-trained and certified evaluators. The evaluators were not informed of the subjects' diagnoses in advance. The MMSE, the MoCA, and the cross-cultural neuropsychological test battery (CCNB), including the Cognitive Ability Screening Instrument (CASI C-2.0), were administered to all participants.
The MMSE, which is widely used as a screening tool to evaluate subjects' general cognitive function, includes five subtest areas: orientation, registration, recall, attention/concentration/calculation and language; scores range from 0 (severe impairment) to 30 (no impairment) 19, 99 . Further, general cognitive function was assessed with the MoCA and CASI C-2.0, which provide more comprehensive assessment than the MMSE. The CASI includes nine domains: long-term memory, short-term memory, attention, concentration, orientation, reasoning (comprising abstraction and judgment), language abilities, visual construction and category fluency 100 . The MoCA is designed specifically for patients with MCI or with mild AD. Executive function, short-term memory, language skills and visuo-spatial processing are categories included on the MoCA test.
Quantitative measurements of APL1β28 and clusterin from human plasma. Plasma APL1β 28 and clusterin concentrations were assayed by commercially available ELISA kits (Human APL1β 28 ELISA, EK-018-42; Human Clusterin ELISA, EK-018-35, Phoenix Pharmaceuticals, Inc.). All samples were run in duplicate.
Apolipoprotein (ApoE) genotype. ApoE genotyping (ε 2, ε 3, and ε 4 allele) was performed on DNA samples from the subjects' blood, as previously described 101 . Statistical analyses. Data analysis was performed using IBM SPSS Statistics 16.0 for Windows.
We first used partial correlation analysis to investigate the associations between the cognitive tests and plasma clusterin and APL1β 28 levels, respectively. Analyses were adjusted for age, sex, ApoE ε 4 status and education when applicable. We then compared differences in plasma clusterin and APL1β 28 concentrations between the MCI and control groups (independent sample t-tests) to test the entire sample for differences in plasma clusterin and APL1β 28 concentrations and found no significant differences. Finally, within the diagnostic categories, group comparisons of continuous variables according to their ApoE ε 4 status were performed using the student's t-test, which revealed no significant differences. A priori level of significance was set at p< 0.05 for all analyses.
